SCHEMBL5897023

SCHEMBL5897023

O=C(Nc1ccc(Cl)c(NC(=O)c2ccc3ncccc3c2)c1)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.72
RAB9A P51151 8/20 0.61
NPC1 O15118 7/20 0.61
POLB P06746 1/20 0.61
HDAC1 Q13547 2/20 0.60
HDAC2 Q92769 1/20 0.60
BRAF P15056 1/20 0.59
MAPT P10636 2/20 0.59
CASP3 P42574 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
SENP6 Q9GZR1 1/20 0.58
ALDH1A1 P00352 2/20 0.57
HTT P42858 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
GRM4 Q14833 1/20 0.57
HSF1 Q00613 1/20 0.56
CSF1R P07333 1/20 0.56
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5897360 0.89 PABPC1 (0.56) PABPC1RAB9ANPC1POLBHDAC1
SCHEMBL5897251 0.87 BRAF (0.76) PABPC1RAB9ANPC1POLBHDAC1
SCHEMBL27509830 0.86 HDAC1 (0.61) PABPC1RAB9ANPC1POLBHDAC1
Hydrochloric Acid SCHEMBL2974700 0.85 HDAC1 (0.60) PABPC1RAB9ANPC1POLBHDAC1
SCHEMBL16621477 0.85 HSF1 (0.79) RAB9ANPC1POLBBRAFMAPT
SCHEMBL6978685 0.84 PABPC1 (1.00) PABPC1RAB9ANPC1POLBMAPT
SCHEMBL29429748 0.84 PABPC1 (1.00) PABPC1RAB9ANPC1POLBMAPT
SCHEMBL5897118 0.84 BRAF (0.69) PABPC1RAB9ANPC1POLBHDAC1
SCHEMBL2976951 0.84 HDAC1 (0.61) PABPC1RAB9ANPC1POLBHDAC1
SCHEMBL5897048 0.83 BRAF (0.71) PABPC1RAB9ANPC1POLBHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7060700-B2 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2006-06-13 US disclosed
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB 2003-06-05 US disclosed
US-6432949-B1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2002-08-13 US disclosed
EP-1102750-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007991-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines IL6, IL6ST, IL2 PABPC1 4273/4885RAB9A 884/4885NPC1 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.